Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00578916 | Pharmacokinetics and Metabolism of Radiolabeled BMS-690514 in Healthy Male Subjects | PHASE1 | COMPLETED | 17 | — | — | Jan 1, 2008 | Jan 1, 2008 | Jul 31, 2008 | 1 | Switzerland |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| EVRI (BMS-690514) | DRUG | Oral Solution, Oral, 200 mg, single dose followed by 10-12 day inpatient stay |
Inclusion Criteria: * Healthy male subjects * Body mass index (BMS) of 18 - 30 kg/m², inclusive Exclusion Criteria: * Radiation exposure from diagnostic X-rays (except dental X-rays) in the last year or from clinical trials in the last 5 years
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520 / GEH200521 - Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | — | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |